REVIEW
155 Fetal fraction and noninvasive prenatal testing: What clinicians need to know
L. Hui and D. W. Bianchi

ORIGINAL ARTICLES
164 A 2-year review of publicly funded cell-free DNA screening in Ontario: utilization and adherence to funding criteria
K. Bellai-Dussault, L. Meng, T. Huang, J. Reszel, M. Walker, A. Lanes, N. Okun, C. Armour and S. Dougan
173 Cell-free DNA for Down syndrome screening in obese women: Is it a cost-effective strategy?
M. K. Hopkins, L. Dugoff, C. Durnwald, L. J. Havrilesky and S. Dotters-Katz
179 Cell-free DNA fetal fraction in twin gestations in single-nucleotide polymorphism-based noninvasive prenatal screening
H. Hedriana, K. Martin, D. Saltzman, P. Billings, Z. Demko and P. Benn
185 The utility of nuchal translucency ultrasound in identifying rare chromosomal abnormalities not detectable by cell-free DNA screening
V. K. Berger, M. E. Norton, T. N. Sparks, M. Flessel, R. J. Baer and R. J. Currier
191 Prenatal diagnosis and postnatal outcome of anterior urethral anomalies
S. Perlman, Y. Borovitz, D. Ben-Meir, Y. Hazan, R. Nagar, R. Bardin, M. Brusilov, B. Dekel, R. Achiron and Y. Gilboa
197 Is there still a role for nuchal translucency measurement in the changing paradigm of first trimester screening?
F. Bardi, P. Bosschieter, J. Verheij, A. Go, M. Haak, M. Bekker, E. Sikkel, A. Coumans, E. Pajkrt and C. Bilardo
206 In fetuses with congenital lung masses, decreased ventricular and atrioventricular valve dimensions are associated with lesion size and clinical outcome
216 Cerebral blood flow dynamic in foetuses with hypoplastic left heart syndrome: Incremental value of the first segment of the anterior cerebral artery over the middle cerebral artery?
Y. Liu, S. Zeng, Y. Tan, J. Zhou and B. Zhao
223 Improving fetal congenital heart disease screening using a checklist-based approach
M. B. Janicki, C. G. Fernandez, D. Wakefield, J. P. Shepherd and R. Figueroa
232 Maceration determines diagnostic yield of fetal and neonatal whole body post-mortem ultrasound
244 Prevalence of mosaicism in uncultured chorionic villus samples after chromosomal microarray and clinical outcome in pregnancies affected by confined placental mosaicism
260 Exome sequencing for perinatal phenotypes: The significance of deep phenotyping

RESEARCH LETTERS
274 High risk for carriers of de novo balanced structural chromosomal aberrations in prenatal diagnosis: Latin America data
L. A. Méndez-Rosado and R. Lardoeyt-Ferrer
276 Prenatal cerebral imaging features of a new syndromic entity related to KIAA1109 pathogenic variants mimicking tubulipathy

CORRESPONDENCE
282 Caution is needed in characterizing fetal posterior fossa malformations with transabdominal ultrasound
D. Paladini
Prenatal Diagnosis welcomes submissions in all aspects of prenatal screening and diagnosis with a particular focus on areas in which molecular biology and genetics interface with prenatal care and therapy, encompassing:

- Prenatal cytogenetics, including microarrays
- Prenatal molecular genetics, including whole exome and whole genome sequencing
- Prenatal diagnosis of single gene disorders, including errors of metabolism
- Fetal transcriptome, proteome and metabolome studies
- Noninvasive testing using fetal cells and cell-free DNA and RNA in maternal blood
- Fetal and placental development and pathology
- Fetal therapy
- Outcome studies of prenatally diagnosed conditions
- Preconceptual, preimplantation and prenatal genetic counseling
- Preimplantation genetics diagnosis and screening
- Psychosocial, legal, ethical and economic aspects of prenatal testing

The overriding criteria for publication are scientific merit, originality, and interest to a multidisciplinary audience. We publish very few case reports. The Journal may be viewed and all manuscripts should be submitted online at www.prenataldiagnosisjournal.org

AIMS & SCOPE

Prenatal Diagnosis is the Official Journal of the International Society for Prenatal Diagnosis (http://www.wiley.com/ispd)